The main purpose of this study is find out how safe a single dose of bryostatin 1 is in patients with Alzheimer's Disease (AD). This study is also being done 1) to determine how effective a single dose of bryostatin 1 is in the treatment of AD, 2) to find out what happens to bryostatin 1 once it enters the body by measuring the levels of bryostatin 1 in blood, and 3) to measure a substance in the blood (protein kinase C) that may help to better understand how bryostatin 1 works.

Use of any drug within 14 days prior to randomization unless the dose of the drug & the condition being treated have been stable for at least 30 days & are expected to remain stable during the study & neither the drug nor the condition being treated is expected to interfere with the study endpoints

Any medical or psychiatric condition that may require medication or surgical treatment during the study

Life expectancy less than 6 months

Any other screening laboratory values outside the normal ranges that are deemed clinically significant by the investigator

Use of an investigational drug within 30 days prior to the screening visit or during the entire study

Previous randomization in this trial or participation in another investigational trial < 2 months prior to randomization

Likelihood, according to clinical judgment, of being transferred to a nursing home within 6 months

Change in dosage of any concomitant antidepressant within 30 days prior to randomization

Lack of caregiver

Pregnant or lactating females

Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedures outlined in this protocol

HIV positive

Hepatitis B or C positive

Concomitant use of medications other than AD or antidepressant medications for which the dose regimens are stabilized for at least 30 days prior to enrollment in study

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00606164

Locations

United States, West Virginia

Chestnut Ridge Center West Virginia University Department of Behavioral Medicine and Psychiatry